Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Insulin for Regulation of Endogenous Glucose Production
NCT02131948Phase 1Completed
- Sponsor
- University Health Network
- Start
- Nov 2013
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of Generex Oral-lyn in diabetes mellitus (DM) and insulin resistance (IR) (2 arms), sponsored by University Health Network. Primary endpoint: Endogenous glucose production at 8 hours. Started Nov 2013; status: completed.
02
Drugs
Generex Oral-lyn
03
Conditions
diabetes mellitus (DM)insulin resistance (IR)
Beyond the preview
Go deeper on NCT02131948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02131948.